To leverage the research expertise and combined manufacturing capacities to introduce first-of-its-kind products in India, the largest CDMO, Akums Drugs & Pharmaceuticals Ltd, has partnered with Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals for research and development of a range of products for multiple therapies. This association is set to bring succour in therapy areas of CNS disorders, Pain management, and Hormonal disorders, where there is a gap in meeting the needs of patients in an effective, safe, and convenient manner. This partnership leverages the strengths of each of the companies resulting in an innovation strategy creating a unique value proposition to doctors and patients in India.

The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years. The agreement was signed at the CPHI event and exhibition on the 30th of November 2022 at Greater Noida in the presence of Prof(Dr). Y.K Gupta, President AIIMS Bhopal & President AIIMS Jammu & Former Dean & HoD Pharmacology, AIIMS Delhi.

“India has a significant contribution to the global pharma market and is rightly named the Pharmacy of the world. Global companies are looking towards India for differentiated research and innovative therapies. I am excited to know that Leiutis, Biophore and Akums have collaborated to introduce such differentiated and speciality products. The entire process, from basic Research API Development and Product Manufacturing is based in India. This is exactly what is exciting for India and expected from Indian entrepreneurs. The innovative products from this association will bring laurels to Indian Pharma Industry.”         

A significantly large number of patients suffer from these diseases in India and globally, requiring treatment for several years and often having suboptimal experience with the available treatment options. In association with LEIUTIS and BIOPHORE, we are committing to bringing unique products made available to the physicians and patients for improved clinical outcomes", said Sanjeev Jain, Founder, Promoter and Director, Akums.

As Dr. Jagadeesh Babu Rangisetty, Founder and CEO of Biophore observes, it is imperative to form such partnerships to bring innovative products to the medical fraternity and patients. "It's such an exciting prospect to partner with two other amazing organisations in the global pharma space. The aim is to combine our key competencies, capacities, and our passion for providing new therapies globally proven through clinical outcomes and to improve the lives of patients", he said.

"Innovative therapies should address two objectives; ameliorate suffering and improve quality of life. Innovation is a collaborative journey & I am very excited to be part of this journey. I am overwhelmed with the impact this association will make by creating value through clinically proven innovations for healthcare providers & patients. Through this association, I look forward to enabling our vision of fostering the well-being of patients through research & innovation. It gives me immense pride to mention that the products, technology, APIs, and manufacturing are developed & made in India.", said K Chandrasekhar, CEO of Leiutis Pharmaceuticals LLP.

This tripartite association will see Akums manufacture & commercialise the products created by Leiutis Pharmaceuticals LLP and API from Biophore.

These unique products will be launched and marketed in India and the rest of the world, in line with our government's vision to” Research in India, Make-in-India, Market globally” especially because of its potential to bring about useful therapies and bridge the gaps in the treatment of ailments and diseases across the world.